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Background. Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment
options for patients with second-stage disease are either highly toxic or impracticable in ﬁeld conditions. We compared the efﬁcacy
and safety of the nifurtimox-eﬂornithine drug combination with the standard eﬂornithine regimen for the treatment of second-
stage disease.
Methods. A randomized, open-label, active-control, phase III clinical trial comparing 2 arms was conducted at the Sleeping
Sickness Treatment Center, which was run by Me ´decins Sans Frontie `res, in Nkayi, Bouenza Province, Republic of Congo. Patients
were screened for inclusion and randomly assigned to receive eﬂornithine alone (400 mg/kg per day given intravenously every 6
h for 14 days) or eﬂornithine (400 mg/kg per day given intravenously every 12 h for 7 days) plus nifurtimox (15 mg/kg per day
given orally every 8 h for 10 days). Patients were observed for 18 months. The study’s outcomes were cure and adverse events
attributable to treatment.
Results. A total of 103 patients with second-stage disease were enrolled. Cure rates were 94.1% for the eﬂornithine group
and 96.2% for the nifurtimox-eﬂornithine group. Drug reactions were frequent in both arms, and severe reactions affected 25.5%
of patients in the eﬂornithine group and 9.6% of those in the nifurtimox-eﬂornithine group, resulting in 2 and 1 treatment
suspensions, respectively. There was 1 death in the eﬂornithine arm and no deaths in the nifurtimox-eﬂornithine arm.
Conclusions. The nifurtimox-eﬂornithine combination appears to be a promising ﬁrst-line therapy for second-stage sleeping
sickness. If our ﬁndings are corroborated by ongoing ﬁndings from additional sites (a multicenter extension of this study), the
new nifurtimox-eﬂornithine combination therapy will mark a major and multifaceted advance over current therapies.
Human African trypanosomiasis (HAT), or sleeping sickness,
remains a public health challenge in sub-Saharan Africa, with
an estimated 50,000–70,000 new cases per year, of which
∼20,000 are detected and reported [1]. The disease is caused
by the protozoan parasite Trypanosoma brucei gambiense,which
is transmitted by the tsetse ﬂy (Glossina species), and it pro-
gresses from the hemolymphatic ﬁrst stage to the meningo-
encephalitic second stage. It is invariably fatal without appro-
priate treatment. Since 1949, melarsoprol is the most
commonly used treatment for second-stage HAT. This arsenical
derivative is associated with severe toxic effects—in particular,
reactive encephalopathy, which is fatal in 10%–70% of cases
and affects 5%–10% of treated patients [2, 3]. Moreover, in-
Received 30 March 2007; accepted 23 May 2007; electronically published 22 October 2007.
Reprints or correspondence: Dr. Gerardo Priotto, Epicentre, 8 rue Saint-Sabin, 75011 Paris,
France (gpriotto@epicentre.msf.org).
Clinical Infectious Diseases 2007;45:1435–42
  2007 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2007/4511-0006$15.00
DOI: 10.1086/522982
creasing melarsoprol failure rates (up to 30%) have been re-
ported in several countries [4–6].
Eﬂornithine (diethylﬂuoromethylornitihine), the only new
drug registered in 58 years for the treatment of second-stage
HAT, is a trypanostatic that inhibits ornithine decarboxylase,
an enzyme essential for cell multiplication and differentiation
[7–9]. It is better tolerated than melarsoprol, and its toxic ef-
fects—mainly seizures, gastrointestinal disorders, and myelo-
suppression—are reversible if well managed. Its efﬁcacyiscom-
parable to that of melarsoprol. However, a major disadvantage
of eﬂornithine is the mode of administration, requiring 1 slow
infusion every 6 h for 14 days (56 infusions in total), a regimen
imposed by its short half-life of 1.5–5 h [10, 11]. The difﬁculty
in administering eﬂornithine in resource-poor settingsexplains
why melarsoprol continues to be the ﬁrst-line treatment.
Nifurtimox is an orally administered drug used in the treat-
ment of Chagas disease (American trypanosomiasis) at dosages
of 8–20 mg/kg per day for 90–120 days. Although it has not
been approved for treatment of HAT, nifurtimox is used for1436 • CID 2007:45 (1 December) • CSE THEME ARTICLE
compassionate treatment of relapsed disease. Its toxicity, which
has been poorly documented, includes mainly neurological
(headache, sleep disorders, agitation, and confusion) and gas-
trointestinal (anorexia, nausea/vomiting, and dyspepsia) dys-
functions [12, 13], some of which increase with the duration
of intake [14, 15]. In the 1970s and 1980s, nifurtimox was
tested empirically in several HAT case series, and the results
were conﬂicting [14–17]. These studies, which applieddifferent
treatment regimens and evaluation criteria, are difﬁcult to
compare.
Drug combinations can potentially avert or delay the emer-
gence of drug-resistant organisms. Dosage reductions of each
drug combined may reduce the overall toxicity while main-
taining good efﬁcacy. Combinations may also allow for a sim-
pler administration of treatment, improving the feasibility of
therapy in remote areas with logistic and stafﬁng limitations.
A ﬁrst attempt to assess various combinations for the treat-
ment of second-stage HAT in Uganda was interruptedbecause
of excess fatality in the melarsoprol-nifurtimoxarm.Although
the results were inconclusive, the trial showed promising
safety and efﬁcacy results with the nifurtimox-eﬂornithine
combination [18]. Assessment of this combination was there-
fore extended to a case study of 31 patients thatyieldedsimilar
results [19].
In 2003, Me ´decins Sans Frontie `res and Epicentre, in collab-
oration with the Ministry of Health, initiated a randomized,
open-label clinical trialinNkayi,RepublicofCongo,toevaluate
the efﬁcacy and toxicity of the nifurtimox-eﬂornithine com-
bination with doses equal to those in the 2 previous studies,
with additional simpliﬁcation of the administration schedule.
In 2005, the study was extended to the Democratic Republic
of Congo and Uganda, in partnership with the Drugs for Ne-
glected Diseases initiative, the World Health Organization Spe-
cial Program for Training and Research in Tropical Diseases,
the Swiss Tropical Institute, and national HAT programs.
METHODS
To facilitate external comparability, the study methodologywas
similar to the methodologies in previous clinicaltrialsinvolving
second-stage HAT [18–22].
Participants. Study participants were identiﬁed among
persons with cases diagnosed at the treatment center or during
active screening. Inclusion criteria were as follows: conﬁrmed
second-stage infection, with trypanosomes detected in speci-
mens of blood, lymph, or CSF, with 120 leukocytes/mL in CSF
specimens. Exclusion criteria were as follows: age, !15 years;
pregnancy; history of second-stage HAT treated during the pre-
ceding 36 months; severe comorbidities likely to lead to early
death during the follow-up period; hemoglobin concentration,
!5 g/dL; or inability to complete 18 months of follow-up for
other reasons.
Three ethics committees approved the study protocol and
protocol amendments: (1) the Me ´decins Sans Frontie `resEthical
Review Board, (2) Comite ´ Consultatif de Protection des Per-
sonnes dans la Recherche Biome ´dicale (Saint-Germain-en-
Laye, France), and (3) the World Health OrganizationResearch
Ethics Review Committee (Geneva, Switzerland). The Con-
golese Ministry of Health issued authorization. All participants
provided written informed consent.
A data safety monitoring board consisting of 4 independent
experts was formed before study initiation. The data safety
monitoring board received regular reports and issued recom-
mendations for the study continuation.
Interventions. Participants were randomized into 1 of 2
arms: the eﬂornithine arm or the nifurtimox-eﬂornithine arm.
A scientiﬁc committee established the dosages on the basis of
published and unpublished evidence. The investigational arm
received eﬂornithine (400 mg/kg per day given intravenously
every 12 h for 7 days) plus nifurtimox (15 mg/kg per day given
in oral tablets every 8 h for 10 days), and the active comparator
arm received eﬂornithine (400 mg/kg per day given intrave-
nously every 6 h for 14 days). Eﬂornithine was infused over a
2-h period and was diluted in 250 mL of normal saline. Ni-
furtimox doses were repeated if vomiting occurred within 30
min. All doses were directly administered and observed by the
medical staff. Before commencement of treatment, all patients
with malaria (as determined by microscopic evaluation and
rapid diagnostic testing) received arthemeter-lumefantrine for
3 days; study treatment was started at least 1.5 days after the
last dose of antimalarial therapy. The administration of drugs
for all other concomitant conditions was postponed until the
end of the hospitalization, unless the clinical need warranted
immediate treatment. Patients and attendants received a food
ration of at least 2100 kcal/day each.
All patients were examined daily and hospitalized for 7 days
after the end of treatment (or longer, if deemed necessary). A
lumbar puncture was performed on the day after the patient
received his or her last dose, and CSF specimens wereexamined
for trypanosomes. Laboratory studies, including lumbar punc-
ture examinations and examinations of blood and lymph spec-
imens, were performed at 3, 6, 12, and 18 months. At each
follow-up visit, the CSF specimen was examined for parasites
after double-centrifugation, a parallel CSF leukocyte count was
determined, and IgM titers in CSF were determined using the
Latex/IgM reagent (Institut de Me ´decine Tropicale) [23], which
aimed at increasing the sensitivity of detection of relapses.
Blood samples were examined by capillary tube centrifugation
and quantitative buffy coat [24]. Lymph was aspirated from
any palpable posterior cervical lymph node.
The study follow-up period was set at 18 months, as rec-
ommended by the Informal Consultation on the Conduct of
Clinical Trials in HAT (World Health Organization, 2004) onCSE THEME ARTICLE • CID 2007:45 (1 December) • 1437
the basis of data that suggested that 70%–90% of relapsesoccur
18 months after the completion of treatment. Although the
study end point was determined at 18 months, the national
protocol required a last follow-up visit at 24 months for all
patients.
The deﬁnition of relapse is not currently standardized. Re-
lapse was diagnosed if trypanosomes were seen in body ﬂuid
specimens or if CSF leukocyte counts increased twice consec-
utively by at least 20 cells/mL any time after the completion of
treatment. Patients who presented with a single increase were
reexamined 1 month later. At the month 18 examination, re-
lapse was diagnosed if the CSF leukocyte count was 20 cells/
mL, regardless of previous counts. Distinction between relapse
and reinfection was not made. The probability of reinfection
was considered to be minimal, because disease transmission
had been substantially reduced after 3yearsofintensivedisease-
control activities by Me ´decins Sans Frontie `res.
Safety was assessed with the international Common Toxicity
Criteria [25], which grade adverse events by intensity from 1
to 4 (for mild, moderate, severe, and very severe, respectively),
drug-event relationship (unrelated, unlikely, possible,probable,
and deﬁnite), and outcome (complete recovery, still present,
sequelae, and death). All patients had a blood sample taken
before and after treatment; the sample was examined for he-
moglobin concentration,totalanddifferentialleukocytecounts,
total bilirubin level, creatinine level, and alanine aminotrans-
ferase level.
Anemia was deﬁned as a hemoglobin concentration !13 g/
dL for male patients and !11 g/dL for female patients that had
decreased by 120%. Leukopenia was deﬁned as a leukocyte
count !4000 cells/mL that had decreased by 130%. Neutropenia
as a neutrophil count !2000 cells/mL that had decreased by
130%.
Alanine aminotransferase, bilirubin, and creatinine levels
were measured by a colorimetric method (Randox) in a sub-
group of patients. The reagents for alanine aminotransferase
were different (Human) for the last 39 patients because of
logistical constraints. Abnormal values were deﬁned as follows:
bilirubin, 117 mmol/L, with a 11.5-fold increase; alanine ami-
notransferase, 112 IU/L (as determined for 43 patients using
the Randox reagents) or 132 IU/L (for female subjects) and
142 IU/L (for male subjects, as determined for 39patientsusing
the Human reagents), with a 12.5-fold increase; and creatinine,
180 mmol/L (for female subjects) and 197 mmol/L (for male
subjects), with a 11.5-fold increase.
Pharmacokinetic analysis of plasma and CSF drug concen-
trations was performed in an ancillary study related to the
clinical trial. The methodology and results will be reported
elsewhere.
Outcomes. The primary outcome was cure. The following
end points were regarded as therapeutic failures: (1) death in
temporal relation to treatment (i.e., 30 days after the com-
mencement of treatment), and (2) relapse of HAT or death
compatible with HAT within the 18 months of follow-up.
Deaths due to disease without clearly established alternative
causality were regarded as compatible with HAT. Secondary
outcomes were the adverse events in temporal relation to treat-
ment, particularly the major adverse events graded as severe
(grade 3) and very severe (grade 4).
Sample size. The sample size to test noninferiority in cure
rates for the complete multicenter study was set at 280 subjects.
This report analyzes the data of the 103 patients enrolled in
Nkayi.
The randomization list (in blocks of 10) was electronically
generated. The list and the block size were concealed from the
ﬁeld team. Participants were enrolled in the same order in
which they received diagnoses. Sealed and numbered opaque
envelopes containing the treatment allocation were opened in
strict numeric sequence. Blinding was unfeasible owing to the
different drug administration modes.
Data management. Data were collected in purposely de-
signed patient charts. Trial-speciﬁc data were extracted onto
case report forms. These data were double-entered electroni-
cally with EpiData, version 3.0 (The EpiData Association), and
were analyzed with Stata, version 9.0 (Stata).Nostatisticalcom-
parisons were performed, because interim analysis would alter
the statistical power of the overall trial.
RESULTS
Participants. Of 630 patients who had HAT diagnosedduring
the trial period, 261 had cases that were in the second stage,
of whom 103 met the entry criteria and were enrolled in the
study (ﬁgure 1). The main reasons for ineligibilitywererelapsed
status, young age, and/orlow CSFleukocytescount.Allenrolled
patients were treated: 51 were treated with eﬂornithine, and 52
were treated with nifurtimox-eﬂornithine.
Enrollment started in August 2003 and was closed in De-
cember 2004 as a result of a decrease in the disease prevalence
in the area, resulting in a low enrollment rate. Patient char-
acteristics were similar in the 2 groups (table 1). Four patients
(2 in each arm) had CSF leukocyte counts of 5–20 cells/mL and
were wrongly enrolled. Because these 4 patients had trypano-
somes in the CSF, they were kept in the study. All patients
received complete treatment in accordance with the protocol.
Outcomes and estimation. One patient died in temporal
relation to the treatment regimen and was considered to have
experienced treatment failure. The large majority of patients
(98 [95.1%] of 103) completed the 18-month follow-up period
or reached the study end point earlier, and the rest (5 [4.9%])
underwent partial follow-up. Of the 5 patients who underwent
partial follow-up, all had demonstrated decreasing CSF leu-
kocyte counts and IgM titers at their last follow-up visit. One1438 • CID 2007:45 (1 December) • CSE THEME ARTICLE
Figure 1. Trial proﬁle. E, eﬂornithine; HAT, human African trypanoso-
miasis; N+E, nifurtimox-eﬂornithine.
aRelapses were detected at 12
months in one patient and 18 months in the other.
bRelapses were de-
tected both at 18 months.
cCondition was controlled at 12 months, with
favorable evolution; patient moved away later.
dOne patienthadcontrolled
disease at 3 and 6 months, with favorable evolution; the patient later
died of cerebral malaria. The other patient had controlled disease at 3,
6, and 12 months, with favorable evolution; the patient later died of
ovarian cancer.
died of cerebral malaria (last follow-up visit was at month 6),
another died after ovarian cancer surgery (last follow-up visit
was at month 12), and 3 moved awayafter themonth12follow-
up visits. There were 4 relapses in total (2 per arm). All 4
patients who experienced relapse had increasing CSF leukocyte
counts without detected trypanosomes; 1 patient had relapse
at 12 months, and 3 had relapse at 18 months. Cure rates were
94.1% (48 of 51 patients) in the eﬂornithine arm and 96.2%
(50 of 52) in the nifurtimox-eﬂornithine arm. If patients with
partial follow-up are excluded from analysis, the cure rates are
93.3% (46 of 49 patients) in the eﬂornithine arm and 95.9%
(45 of 49) in the nifurtimox-eﬂornithine arm.
Paired before-after treatment CSF IgM titers were available
for 88 patients. Blood contamination of CSF (6% of specimens)
and other constraints (1% of specimens) explain the missing
measurements. Lumbar puncture was performed 12 h after the
last dose of eﬂornithine and revealed that the titers decreased
in 40 (46%) of 88 patients, stayed unchanged in 38 patients
(43%), and increased in 10 patients (11%). The evolution of
the IgM titer values during follow-up ( ) showed a con- n p 102
sistent decrease over time. Only in patients who experienced
relapse did increases in IgM titers accompany increases in CSF
leukocyte counts.
Drug reactions. Only 1 patient, who was in theeﬂornithine
group, died within 30 days after the start of treatment; this
death was attributed to septic shock following severe neutro-
penia. Of a total of 261 adverse events, 14 were classiﬁed as
unrelated to treatment, and 247 were regarded asdrugreactions
(table 2). Noteworthy differences in overall toxicity included
fever, hypertension, and diarrhea, all of which were less com-
mon in the nifurtimox-eﬂornithine arm. On the other hand,
the combination more frequently provoked nausea and vom-
iting, which tended to appear 1 h after the simultaneous
administration of both drugs (for the ﬁrst daily dose) and less
frequently when the drugs were administered at differenttimes.
There were 14 major drug reactions (i.e., those of grades 3
and 4) in the eﬂornithine arm and 6 such reactions in the
nifurtimox-eﬂornithine arm, and the proportions of patients
who experienced major reactions were 25.5% and 9.6% per
arm, respectively (table 2). Treatment was suspended because
of severe complications for 2 patients in the eﬂornithine arm
and 1 patient in the nifurtimox-eﬂornithine arm. These inter-
ruptions were made as a result of seizures (1 patient in each
arm) and arrhythmia (1 in the eﬂornithine arm). The 6 major
adverse events observed in the nifurtimox-eﬂornithine arm
were seizures (4 patients), fever (1 patient), and neutropenia
(1 patient), all of which resolved favorably.
Before-and-after treatment hematologic data were available
for all patients. Neutropenia and anemia were the most com-
mon biological adverse events, appearing 3 times more fre-
quently in the eﬂornithine arm. Grade 3 neutropenia (i.e., a
neutrophil count !1000 cells/mL) developed in 6 patients in the
eﬂornithine arm, compared with only 1 patient in the nifur-
timox-eﬂornithine arm. Abnormal biochemical values were
rare and mild.
DISCUSSION
The results obtained with the nifurtimox-eﬂornithine combi-
nation are similar to those obtained with standard eﬂornithine
treatment, even showing a trend of superiority in the safety
parameters. These data conﬁrm the observations made in our
earlier studies from Uganda [18, 19]. With nearly complete
follow-up data for patients (100% reviewed at least 2 times and
95% with complete follow-up), the high cure rates are
reassuring.
The fact that 3 of the 4 relapses were detected at the month
18 visit, having been controlled at 12 months, suggests that the
follow-up in clinical studies should be no shorter than 18
months. The lower occurrence of major drug reactions in the
nifurtimox-eﬂornithine arm suggests a better safety proﬁle of
the combination.
Neutropenia occurred more frequently among recipients of
eﬂornithine alone than among recipients of combination treat-CSE THEME ARTICLE • CID 2007:45 (1 December) • 1439
Table 1. Baseline characteristics of trial participants, by treatment arm.
Characteristic
Eﬂornithine arm
(n p 51)
Nifurtimox-
eﬂornithine arm
(n p 52)
Demographic characteristics
Female sex 23 (45.1) 26 (50.0)
Age, mean years (range) 36.1 (15–70) 33.1 (15–69)
Weight, mean kg   SD 53.1   7.2 51.7   7.4
Mean body mass index
a   SD 19.7   2.2 19.1   2.0
Body mass index
a !18.5 15 (29.4) 22 (42.3)
Parasitologic ﬁndings
Case detected by active screening 29 (56.9) 31 (59.6)
Presence of trypanosomes
In lymph nodes 40 (78.4) 36 (69.2)
In blood 47 (92.2) 42 (80.8)
In CSF 37 (72.6) 30 (57.7)
Leukocyte count in CSF
5–20 cells/mL 2 (3.9) 2 (3.9)
21–99 cells/mL 10 (19.6) 19 (36.5)
100 cells/mL 39 (76.5) 31 (59.6)
IgM titer in CSF 11:128
b 28 (57.1) 20 (40.8)
Clinical characteristics
Mean Karnofsky score   SD 84.6   9.6 80.9   15.9
Mean Glasgow coma score   SD 15.0   0.1 14.8   0.8
Hemoglobin concentration, mean g/dL   SD 12.7   1.9 13.0   1.8
Presence of malaria parasites 14 (27.5) 11 (21.2)
Lymphadenopathy 40 (78.4) 36 (69.2)
Hepatomegaly 2 (3.9) 5 (9.6)
Splenomegaly 14 (27.5) 11 (21.2)
Headache 35 (68.6) 38 (73.1)
Fever
c 13 (25.5) 2 (3.8)
Pruritus 33 (64.7) 33 (63.5)
Daytime somnolence 35 (68.6) 32 (61.5)
Insomnia 18 (35.3) 16 (30.8)
History of seizures 5 (9.8) 4 (7.7)
Psychiatric signs 25 (49.0) 21 (40.4)
Speech disorder 8 (15.7) 9 (17.3)
Impotence or amenorrhea 15 (29.4) 19 (36.5)
Tremors 20 (39.2) 18 (34.6)
Anorexia 6 (11.8) 12 (23.1)
Duration of symptoms, mean months (range) 9.8 (1–72) 8.7 (0–24)
NOTE. Data are no. (%) of patients, with the percentages indicating proportion of the entire
cohort, unless otherwise indicated.
a Body mass index was calculated as weight in kilograms divided by the square of height in
meters. A body mass index !18.5 was considered to indicate thinness.
b IgM titer data were available for 98 patients (49 in the eﬂornithine arm and 49 in the nifurtimox-
eﬂornithine arm).
c Temperature, 37.5 C, axillary.
ment, which contains half as much eﬂornithine. Patients with
grade 3 neutropenia are vulnerable to bacterial infection,which
explains the frequent infectious complications emergingduring
or after treatment, as well as the only death in our cohort. The
combination clearly offers improved safety over melarsoprol,
which causes reactive encephalopathy in 5%–10% of recipients,
with a high fatality rate. There were no clinical data to support
theoretical concerns about toxicity related to drug interactions
with the combination therapy.
Nkayi presented unusual advantages in comparison to mostTable 2. Clinical and biological drug reactions during hospitalization.
Event
No. (%) of events
Eﬂornithine arm
(n p 51)
Nifurtimox-
eﬂornithine arm
(n p 52)
All Major All Major
Treatment-related death 1 (2.0) … 0 (0.0) …
Neurologic reactions
Seizures 2 (3.9) 2 4 (7.7) 4
Confusion 0 (0.0) … 1 (1.9) …
Anxiety and/or agitation 4 (7.8) … 2 (3.8) …
Dizziness 1 (2.0) … 1 (1.9) …
Insomnia 1 (2.0) … 2 (3.8) …
Gastrointestinal reactions
Anorexia 0 (0.0) … 1 (1.9) …
Abdominal pain 11 (21.6) … 10 (19.2) …
Diarrhea 4 (7.8) … 0 (0.0) …
Constipation 0 (0.0) … 2 (3.8) …
Nausea and/or vomiting 8 (15.7) … 26 (50.0) …
Cardiovascular reactions
Arrythmia 3 (5.9) … 1 (1.9) …
Hypertension 8 (15.7) 1 1 (1.9) …
Edema 4 (7.8) … 0 (0.0) …
Infection
Tissue infection 1 (2.0) … 1 (1.9) …
Septic shock (neutropenic) 1 (2.0) 1 0 (0.0) …
Other infection 2 (3.9) 1 3 (5.8) …
Other clinical events
Fever
a 13 (25.5) 2 5 (9.6) 1
Headache 15 (29.4) … 13 (25.0) …
Cough 3 (5.9) … 0 (0.0) …
Pruritus 7 (13.7) … 3 (5.8) …
Skin rash 3 (5.9) … 0 (0.0) …
Chest pain 3 (5.9) … 0 (0.0) …
Myalgia and/or arthralgia 3 (5.9) … 3 (5.8) …
Other 2 (3.9) … 4 (7.7) …
Biological reactions
Anemia 11 (21.6) 1 4 (7.7) 0
Leukopenia 1 (2.0) 0 2 (3.8) 0
Neutropenia 29 (56.9) 6 11 (21.2) 1
Abnormal bilirubin level
b 1 (2.0) … 2 (3.8) …
Abnormal alanine aminotransferase level
c 0 (0.0) … 0 (0.0) …
Abnormal creatinine level
c 0 (0.0) … 1 (1.9) …
Weight loss 5% 0 (0.0) … 3 (5.8) …
Total no. of events
d 141 14 106 6
No. (%) of patients who experienced major events … 13 (25.5) … 5 (9.6)
Treatment interruption 2 (3.9) … 1 (1.9) …
Treatment suspension 2 (3.9) … 1 (1.9) …
Treatment termination 0 (0.0) … 0 (0.0) …
NOTE. Percentages indicate the proportion of the entire cohort. “Major” indicates an event of
grade 3 or 4 using the National Cancer Institute Common Toxicity Criteria [25].
a Temperature, 37.5 C, axillary.
b Data were available for 83 patients (41 in the eﬂornithine arm and 42 in the nifurtimox-eﬂornithine
arm).
c Data were available for 82 patients (41 in each arm).
d In the eﬂornithine arm, there were 2.8 adverse events per patient and 0.3 major adverse events
per patient; in the nifurtimox-eﬂornithine arm, there were 2.0 adverse events per patient and 0.1
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other HAT foci, including sociopolitical stability, the supply of
electricity, the availability of internet communication, daily
ﬂights to the capital, good hospital infrastructure, andqualiﬁed
medical staff. The study did not achieve the planned sample
size of 280 subjects in Nkayi because of bureaucratic delays
that resulted in the bulk of patients being detected and treated
by Me ´decins Sans Frontie `res before enrollment could begin.
There were, however, some advantages to this situation: the
smaller caseload facilitated good medical supervision and eased
laboratory work. With a decreased prevalence of disease, the
probability of reinfection during follow-up was alsominimized.
Limitations. As a result of the insufﬁcient number of pa-
tients recruited at this site, we have not yet performed the
noninferiority analysis designed in the protocol; this will only
be possible when the studies from additional sites are com-
pleted. Therefore, these data should not be regarded as deﬁn-
itive proof.
Overall evidence. In the face of unsatisfactory therapeutic
options for second-stage sleeping sickness, the need to identify
new, safe, feasible, and effective therapiesisurgent[3].Research
is hampered by the fact that foci with high caseloads that can
sustain good enrollment rates are often affected by conﬂict and
located in isolated and impoverished parts of Africa. Gathering
the minimal elements for quality research projects (e.g., qual-
iﬁed personnel, infrastructure, communications, andstableand
functional logistics) at such sites represents a challenge that
very few researchers are willing to assume.
Even if, at this ﬁrst study site, we did not attain the complete
sample size, we believe that our data are of crucial interest
because of the promising efﬁcacy and safety results of the ni-
furtimox-eﬂornithine combination, which was tested here for
the ﬁrst time with a simpler (twice-daily) eﬂornithine admin-
istration schedule.
The short half-life of eﬂornithine theoretically requires
shorter administration intervals for effective therapy, and this
was one of the key issues addressed in this study. We hypoth-
esize that this adverse pharmacokinetic proﬁle may be balanced
by the long-lasting pharmacodynamic effect on trypanosomes,
explained by the long time (18–19 h) needed by T. brucei gam-
biense to replenish theirornithinedecarboxylaseafterinhibition
by eﬂornithine [26]. This would give sufﬁcient opportunity for
trypanocydal nifurtimox to eliminate the parasites. Our data
seem to conﬁrm that the 12-h intervals are possible if the agent
is combined with nifurtimox.
The simpliﬁed regimen in this nifurtimox-eﬂornithine
schedule, which involves 4-fold fewer eﬂornithine infusions
(i.e., 14 infusions instead of 56), represents an important ad-
vance in terms of access to safer and effective treatment. Most
treatment centers are located near disease transmission foci, in
remote areas where logistical means and trained staff arescarce,
and most patients need treatment for second-stage disease.The
twice-per-day infusions are key because they ﬁt well in the
routine of rural health facilities. Another important advantage
is the cost reduction coming from the shorter hospitalization
durations and from the 4-fold reduction in the number of
intravenous infusions, requiring fewer infusion materials and
logistics and less stafﬁng.
A degree of protection against the development of drug re-
sistance can also be expected from combination versus mono-
therapy, as is the case for drug combinations in use for other
infectious diseases. In the context of increasing parasite resis-
tance to melarsoprol, and because eﬂornithine is the only al-
ternative agent for second-stage HAT, the availability of a com-
bination treatment regimen is urgent, to avert the development
of eﬂornithine resistance as well.
Because these new data reinforce the evidence in favor of
the nifurtimox-eﬂornithine combination, timely completionof
the additional sites and ensuring good follow-up of patients
are essential. It will also be necessary to organize ﬁeld studies
with simpler—but sound—methodology to assess the admin-
istration of treatment in more-realistic situations. Studies of
children will also be needed. For all this to be possible, the
continued production and availability of nifurtimox must be
ensured. If our ﬁndings are corroborated by ongoing studies
from additional sites (i.e., from a multicenter extension of this
study), the new nifurtimox-eﬂornithine combination therapy
will mark a major and multifaceted advance over current
therapies.
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